September 4, 2012
Valuing Aastrom Biosciences (ASTM) at $4.90 with a Strong BUY ranking
August 27, 2012
NeoStem (NYSE MKT: NBS) No monetary offering, filings tidy up the books and the cap structure
August 14, 2012
NeoStem (NYSE MKT: NBS) Business Update
August 9, 2012
Cytori (CYTX) Expands European Approval
August 6, 2012
StemCells (STEM) Back from the dead but, with share pricing sustainability doubts
July 30, 2012
Osiris Therapeutics (OSIR) Q2/12 Results
July 25, 2012
Histogenics Closes $49M Series A Fundraising
June 12, 2012
ImmunoCellular (Amex: IMUC) Agreeing with Adam Feuerstein
May 31, 2012
Tengion (TNGN), Regaining Compliance by Reverse Split of 1-for-10
May 10, 2012
Aastrom Biosciences (ASTM) Q1/12 Results and Highlights
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.